Whalesbook
Dividend Ka Dhamaka, Par Chinta Ki Baatein?
GSK Pharma ne May 29, 2026 ko record date rakha hai apne shareholders ke liye iss ₹57 ke hefty dividend ka. Is quarter mein company ka net profit ₹278 crore raha, jo last year se 5.7% zyada hai. Revenue bhi thoda sa, 2.1% badhkar ₹995.3 crore tak pahuncha. EBITDA bhi 5.3% badhkar ₹351 crore ho gaya aur margin 35.3% par aa gaya. Numbers steady dikh rahe hain, par growth rate thoda dheema hai.
Growth Ka Slowdown Aur Parent Company Ka Alag Rasta
Indian pharma sector mein abhi 8.1% ke CAGR se growth expected hai, lekin GSK Pharma ka revenue growth Q4 mein sirf 2.1% raha, jo sector averages se kaafi kam hai. Isse lagta hai ki company market share maintain karne mein struggle kar rahi hai ya fir competitors zyada tez hain. Market cap ₹41,663 crore hai aur P/E ratio 41.4x hai, jo Sun Pharma (around 39-40x) ke aas paas hai par Divi's Labs (over 70x) se kam.
Aur haan, GSK Pharma ka global parent, GSK plc, bilkul alag strategy follow kar raha hai. Woh 13-13.2x ke P/E par trade karta hai aur 3.5-3.8% dividend yield deta hai, jiska payout ratio sirf 46-48% hai. Indian subsidiary ka 93.1% payout ratio isse kaafi alag hai.
Dividend Sustainability Par Sawal
Sabse badi chinta hai dividend ki sustainability. Pichhle 5 saal mein company ki sales growth sirf 3.06% rahi hai. Jab growth itni slow ho aur payout ratio 93.1% jaisa high ho, toh yeh sawal uthta hai ki company apne earnings ka itna bada hissa distribute kar degi toh future growth ke liye paisa kahaan se aayega? Ya debt kaise manage hoga?
Analysts bhi isko lekar confuse hain. Motilal Oswal ne 'NEUTRAL' rating di hai aur target ₹1340 rakha hai, jo abhi ke price se kam hai. ICICI Securities ne 'ADD' rating di hai par target ₹2250 hai. Yeh mix sentiment dikhata hai ki market bhi future performance ko lekar sure nahi hai. Plus, Indian pharma ab API manufacturing par focus kar raha hai, jiska GSK Pharma ke formulation business par kya asar hoga, yeh bhi dekhna baaki hai.
Aage Kya Ho Ga?
Indian pharma sector ka future toh achha dikh raha hai, par GSK Pharma ko agar survive karna hai aur grow karna hai, toh unhein apni sales growth speed up karni padegi aur dividend policy ko strategic investment ke saath balance karna hoga.